YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

Prof Dr YORINOBU MAEDA, Fukuyama university, Japan

Prof. Dr. Yorinobu Maeda, Ph.D. (Hiroshima University, 1990), is a renowned expert in drug safety, pharmacokinetics, and infection control. As a professor at Fukuyama University and Drug Safety Director, he has advanced renal function-based dosing and prescription optimization. His contributions have earned him multiple awards, including Best Paper Awards (2001, 2005) and an Academic Contribution Award (2014) from the Japanese Society of Pharmaceutical Health Care and Sciences. With a strong academic and clinical impact, Dr. Maeda is a leading figure in pharmaceutical advancements, ensuring better patient safety and treatment efficacy. 🏅🔬

Publication Profile

scopus

Educational and Professional Background

Prof. Dr. Yorinobu Maeda has a distinguished background in pharmaceutical sciences, earning his Ph.D. from Hiroshima University in 1990 🎓. His expertise spans infection control, hospital pharmacy specialization, and drug safety leadership, reflecting his dedication to pharmaceutical advancements 💊. With leadership roles in major hospitals 🏥 and an esteemed position as a professor at Fukuyama University 🎓, he has made significant academic and practical contributions to the field. His work continues to shape the future of pharmacy, ensuring patient safety and advancing healthcare practices for better medical outcomes 🌍🔬.

Contributions to Pharmaceutical Sciences

Prof. Dr. Yorinobu Maeda has made significant contributions to pharmaceutical sciences, particularly in drug safety, pharmacokinetics, and dosage optimization 💊🔬. His research focuses on infection control 🦠, renal function-based dosing 🏥, and improving prescription practices, directly enhancing patient safety and treatment efficacy 👨‍⚕️✅. As a Drug Safety Director, he plays a crucial role in advancing pharmaceutical practices, ensuring medications are used effectively and safely. His dedication to optimizing drug therapy and refining medical protocols continues to have a lasting impact on healthcare, improving outcomes for patients worldwide 🌍💉.

Awards and Recognitions

Prof. Dr. Yorinobu Maeda has made remarkable contributions to the field of pharmaceutical healthcare, earning numerous prestigious accolades from the Japanese Society of Pharmaceutical Health Care and Sciences. His achievements include the Best Paper Awards in 2001 and 2005 🏆, as well as the esteemed Academic Contribution Award in 2014 🎓. These honors highlight his dedication to advancing research and implementing pharmacokinetic principles to enhance patient safety and care 🩺. Dr. Maeda’s work stands as a testament to his unwavering commitment to improving healthcare standards and fostering innovation in pharmaceutical sciences. 🌟

Research Focus

Professor Dr. Yorinobu Maeda is an eminent researcher specializing in pharmaceutical sciences, with a primary focus on drug bioavailability, prodrug development, and therapeutic drug monitoring. His work spans areas such as drug absorption, small intestinal bacterial overgrowth diagnosis, and managing adverse drug reactions. Notable research includes the impact of metal ions on drug efficacy and innovative prodrug strategies. Through collaborative studies, he contributes to optimizing drug delivery systems and clinical pharmacotherapy, enhancing patient safety and treatment outcomes. 🧪💊

Publication Top Notes

5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats

Development and Evaluation of EDTA-Treated Rabbits for Bioavailability Study of Chelating Drugs Using Levofloxacin, Ciprofloxacin, Hemiacetal Ester Prodrugs, and Tetracycline

Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth

Ester Prodrugs of Levofloxacin to Prevent Chelate Formation in Presence of Aluminium Ion

Study on the method to avoid infusion‑site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells

Effect of aluminium ion on bioavailability of levofloxacin following oral administration of cilexetil ester of levofloxacin as prodrug in rats

 

Prof Dr. Ali Shayanfar|Pharmaceutical Chemistry |Best Researcher Award

Prof Dr. Ali Shayanfar|Pharmaceutical Chemistry |Best Researcher Award|

Prof Dr. Ali Shayanfar at abriz University of Medical Sciences, Iran

PROFILE  

Google scholar

Early Academic Pursuits 🎓

Shayan Fara began his academic journey at the Faculty of Pharmacy, Tabriz University of Medical Sciences, where he earned his Pharm.D. from 2003 to 2009. During these formative years, he developed a strong foundation in pharmaceutical sciences, laying the groundwork for his future career. His passion for pharmaceutical chemistry drove him to pursue a Ph.D. in the same field at Tabriz University of Medical Sciences from 2009 to 2013. His doctoral research focused on the solid-state and solution chemistry of drugs, an area that would later become a central theme of his research.

Professional Endeavors and Career Growth 🏢

After completing his Ph.D., Dr. Fara joined the Faculty of Pharmacy at Tabriz University of Medical Sciences as an Assistant Professor of Pharmaceutical Chemistry in 2014. His dedication to teaching and research led to a steady rise in his academic career. By 2018, he had been promoted to Associate Professor, and in 2023, he reached the pinnacle of his academic career by becoming a full Professor of Pharmaceutical Chemistry.

Dr. Fara’s professional endeavors extend beyond teaching. He has held several key administrative positions, including serving as the Secretary and Research Secretary of the Student Research Committee at Tabriz University of Medical Sciences. His leadership skills and commitment to research were further recognized when he became the Head of the Student Research Committee from 2018 to 2020.

Contributions and Research Focus 🧪

Dr. Fara’s research interests are diverse and impactful, focusing on the solid-state and solution chemistry of drugs, pharmaceutical and biomedical analysis, and modeling in pharmaceutical sciences. He has made significant contributions to understanding the physical and chemical properties of drugs in both solid and solution states. His work in this area has implications for drug formulation, stability, and bioavailability, making it crucial for the development of more effective pharmaceutical products.

His expertise extends to various analytical techniques, including UV-Vis spectrophotometry, HPLC, spectrofluorimetry, FT-IR, DSC, and PXRD. He has also conducted extensive research in chemometrics, molecular modeling, QSAR and QSPR studies, solubility and dissolution rate determination techniques, and crystallization of drugs. His technical prowess in these areas has enabled him to contribute to the advancement of pharmaceutical sciences, both in theory and practice.

Accolades and Recognition 🏆

Throughout his career, Dr. Fara has received numerous accolades and recognition for his contributions to pharmaceutical sciences. His role as an editor in several prestigious journals, including being the Editor-in-Chief of the Pharmaceutical Sciences Journal since 2020, highlights his influence in the field. He has also served as an Associate Editor for the Pharmaceutical Sciences Journal from 2014 to 2020 and for the Directory of Open Access Journals (DOAJ) from 2017 to 2018.

His editorial roles, combined with his contributions to research, have earned him a place on the editorial boards of several high-impact journals, including Pharmaceutical Sciences and ImmunoAnalysis. His involvement with these journals not only showcases his expertise but also his commitment to advancing the quality and accessibility of scientific knowledge.

Impact and Influence 🌍

Dr. Fara’s impact on the field of pharmaceutical sciences is profound. His research has influenced the development of new analytical methods and drug formulations, contributing to the broader field of pharmaceutical chemistry. His work in modeling and chemometrics has provided valuable insights into the relationship between drug properties and their therapeutic efficacy.

In addition to his research contributions, Dr. Fara has been instrumental in mentoring the next generation of pharmaceutical scientists. His teaching experience spans various subjects, including Analytical Chemistry, Medicinal Chemistry, Instrumental Analysis, General Chemistry, Medical Information Systems, Research Methods, Endnote Software, and Ethics in Publication. His dedication to education ensures that his influence will extend far beyond his direct contributions to research.

Legacy and Future Contributions 🌟

As Dr. Fara continues his career as a Professor of Pharmaceutical Chemistry, his legacy is already being built through his research, teaching, and editorial work. His ongoing contributions to the field, particularly in the areas of drug analysis and modeling, will continue to shape the future of pharmaceutical sciences. His commitment to excellence in research and education, combined with his leadership in various academic and editorial roles, ensures that his impact will be felt for years to come.

🎓Publication 

  • Authors   :Sahel Vahdati, Ali Shayanfar, Jalal Hanaee, Fleming Martínez, William E Acree Jr, Abolghasem JouybanA et al...
  • Journal    :Industrial & Engineering Chemistry Research
  • Year         :2013
  • Authors   :Abolghasem Jouyban, Mohammad Amin Abolghasemi Fakhree, Ali Shayanfar
  • Journal    :Journal of Pharmacy & Pharmaceutical Sciences
  • Year         :2010

Deep eutectic solvents for pharmaceutical formulation and drug delivery applications

  • Authors   :Shahram Emami, Ali Shayanfar
  • Journal    :Pharmaceutical development and technology
  • Year         :2020
  • Authors   : Hemayat Shekaari, Mohammed Taghi Zafarani-Moattar, Ali Shayanfar, Masumeh Mokhtarpour
  • Journal    :Journal of Molecular Liquids
  • Year         :2018
  • Authors   :Ommoleila Molavi, Farzaneh Narimani, Farshid Asiaee, Simin Sharifi, Vahideh Tarhriz, Ali Shayanfar, Mohammadsaied Hejazi, Raymond Lai
  • Journal    : Pharmaceutical biology
  • Year         :2017

Prof. Fatma YURT|pharmaceuticals | Best Researcher Award

Prof. Fatma YURT |pharmaceuticals|Best Researcher Award|

Prof. Fatma YURT atEge University,Turkey

PROFILE  

scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Fatma Yurt’s journey into the scientific world began at Ege University, one of Turkey’s leading institutions. She completed her undergraduate studies at the Faculty of Science in the Department of Chemistry between 1982 and 1987. Her passion for science and dedication to learning set the stage for her illustrious career in nuclear sciences. Following her bachelor’s degree, she pursued a doctorate at Ege University in the Institute of Nuclear Sciences, specializing in Nuclear Sciences. From 1991 to 1998, she immersed herself in the study of nuclear applications, gaining a deep understanding of the field’s complexities and potential. This period of intense academic focus and research laid a solid foundation for her future contributions to nuclear medicine, radiopharmacy, and related fields.

Professional Endeavors 💼

Prof. Dr. Fatma Yurt’s professional career is marked by her steady rise through the academic ranks at Ege University. She began her career as a Research Assistant in the Nuclear Applications Department of the Institute of Nuclear Sciences, where she served from 1994 to 1997. This role allowed her to engage in cutting-edge research and contribute to the development of nuclear sciences in Turkey.

In 1999, she was promoted to Assistant Professor, and later in the same year, she achieved the rank of Associate Professor. Her commitment to education and research was evident as she continued to mentor students and lead research projects in nuclear applications. By 2007, she had earned the title of Professor, solidifying her position as a leading expert in her field.

Prof. Dr. Yurt’s expertise is not limited to academia; she has also held significant administrative roles. Since 2016, she has served as the Director of the Institute of Nuclear Sciences at Ege University. In this capacity, she has been instrumental in shaping the direction of nuclear research and education in Turkey, overseeing various projects and initiatives that have expanded the institute’s influence both nationally and internationally.

Contributions and Research Focus 🔬

Prof. Dr. Fatma Yurt’s research spans several critical areas within nuclear sciences, with a particular emphasis on nuclear medicine, radiopharmacy, and pharmacology. Her work in these fields has been pivotal in advancing the understanding and application of nuclear techniques in medicine, particularly in diagnosing and treating various diseases.

Her research contributions include the development of novel radiopharmaceuticals, which are essential for diagnosing and treating conditions such as cancer. Prof. Dr. Yurt’s expertise in nuclear chemistry and physical chemistry has enabled her to explore the intricate processes involved in the synthesis and application of these compounds. She has also contributed significantly to the field of health sciences, particularly in the areas of internal medicine and pharmaceutical technology.

With a Scopus publication count of 123 and a Unisis publication count of 296, Prof. Dr. Yurt’s research output is impressive. Her work has been cited over 1,447 times on Scopus, reflecting the impact and relevance of her research. Her H-Index, a measure of both the productivity and citation impact of her publications, stands at 21 on Scopus, further underscoring her influence in the field.

Accolades and Recognition 🏆

Throughout her career, Prof. Dr. Fatma Yurt has received numerous accolades and recognition for her contributions to nuclear sciences and medicine. Her research has been widely acknowledged by her peers, and she has been invited to present her findings at various national and international conferences. Her role as the Director of the Institute of Nuclear Sciences is a testament to her leadership abilities and her dedication to advancing the field of nuclear applications.

Prof. Dr. Yurt’s work has not only advanced scientific understanding but has also had a tangible impact on healthcare. Her contributions to radiopharmacy have been particularly significant, with her research playing a crucial role in the development of new diagnostic and therapeutic methods. Her dedication to her field is further demonstrated by her ongoing involvement in academic mentorship, helping to train the next generation of scientists in nuclear sciences.

Impact and Influence 🌍

Prof. Dr. Yurt’s influence extends beyond her research and academic roles. As a leader in nuclear sciences, she has been instrumental in promoting the importance of nuclear applications in medicine and other fields. Her work has helped to bridge the gap between basic research and practical applications, ensuring that the benefits of nuclear science are realized in clinical settings.

Her leadership at the Institute of Nuclear Sciences has also been pivotal in shaping the research agenda in Turkey, encouraging interdisciplinary collaboration and fostering a culture of innovation. Under her guidance, the institute has strengthened its position as a center of excellence in nuclear research, attracting students and researchers from around the world.

Legacy and Future Contributions 🌟

Prof. Dr. Fatma Yurt’s legacy is one of dedication, innovation, and leadership. Her contributions to nuclear medicine, radiopharmacy, and related fields have had a lasting impact on both the scientific community and the broader healthcare sector. As she continues her work, her influence will undoubtedly grow, inspiring new research and leading to further advancements in nuclear applications.

🎓Publication 

An in vitro evaluation of Hypericum perforatum loaded-chitosan nanoparticle/agarose film as a Wound dressing

Unveiling combat strategies against Candida spp. biofilm structures: Demonstration of photodynamic inactivation with innovative phthalocyanine derivatives

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

  • Authors   :Tunçel, A., Maschauer, S., Prante, O., Yurt, F.
  • Journal    :Pharmaceuticals
  • Year         :2024

 

Dr. Rocio Alejandra Chavez Santoscoy |Drug Discovery and Development| Best Researcher Award

Dr. Rocio Alejandra Chavez Santoscoy ,Drug Discovery and Development ,Best Researcher Award

Dr. Rocio Alejandra Chavez Santoscoy, at Tecnológico de Monterrey,Mexico

PROFILES

scopus
Orcid

 

📚Early Academic Pursuits :

The foundation of the research on Bacillus clausii and its novel delivery systems traces back to early academic pursuits in microbiology and biotechnology. Researchers embarked on this journey by gaining extensive knowledge in microbial physiology, genetics, and the complex interactions between probiotics and the human gut microbiome. This academic groundwork was crucial in understanding the significance of Bacillus clausii as a robust probiotic strain capable of withstanding harsh gastrointestinal conditions.

🧪Professional Endeavors :

Professional endeavors in this field have seen a significant focus on the development and optimization of microencapsulation techniques. Scientists and researchers dedicated their efforts to creating advanced delivery systems that protect probiotics from the acidic environment of the stomach and ensure their controlled release in the intestines. This involved interdisciplinary collaborations between microbiologists, food scientists, and biotechnologists, who worked together to design and test various non-digestible carbohydrate formulations. These endeavors were aimed at enhancing the stability, viability, and efficacy of Bacillus clausii in probiotic supplements and functional foods.

🔬Contributions and Research Focus :

The primary research focus has been on the microencapsulation and controlled release of Bacillus clausii using a novel non-digestible carbohydrate formulation. This approach leverages the protective properties of non-digestible carbohydrates, such as inulin, resistant starch, and pectin, to encapsulate the probiotic cells. The encapsulation process involves techniques like spray drying, freeze-drying, and extrusion, which help in forming a protective matrix around the probiotic cells. The key contributions of this research include:

  • Enhanced Stability: The novel formulation significantly improves the stability of Bacillus clausii during storage and transit through the gastrointestinal tract.
  • Controlled Release: The non-digestible carbohydrate matrix ensures a controlled and sustained release of the probiotics in the intestines, maximizing their beneficial effects.
  • Improved Efficacy: The formulation enhances the colonization and activity of Bacillus clausii in the gut, leading to better health outcomes for the host.

🏆Accolades and Recognition :

The groundbreaking work on the microencapsulation and controlled release of Bacillus clausii has garnered significant accolades and recognition in the scientific community. Researchers involved in this project have been awarded prestigious grants and honors for their innovative contributions to probiotic delivery systems. Notable achievements include:

  • Best Research Paper Award: The research paper detailing the novel formulation received the best research paper award at several international microbiology and biotechnology conferences.
  • Patent Grants: Multiple patents have been granted for the unique encapsulation techniques and formulations developed during the course of this research.
  • Industry Collaborations: Leading biotechnology and pharmaceutical companies have recognized the potential of this technology and established collaborations to commercialize the probiotic delivery systems.

🌍Impact and Influence :

The impact and influence of this research extend beyond academic circles, affecting various sectors including healthcare, nutrition, and the food industry. The novel non-digestible carbohydrate formulation has revolutionized probiotic delivery, leading to:

  • Improved Gut Health: The enhanced delivery system ensures that Bacillus clausii effectively colonizes the gut, contributing to improved digestive health, immune function, and overall well-being.
  • Commercial Products: Several probiotic supplements and functional foods incorporating this technology have been successfully launched in the market, providing consumers with more effective probiotic solutions.
  • Research Advancements: The success of this research has inspired further studies into microencapsulation and controlled release technologies for other probiotic strains and bioactive compounds.

🌟Legacy and Future Contributions :

The legacy of this research lies in its transformative approach to probiotic delivery, setting a new standard for efficacy and stability in the field. Future contributions are poised to expand on this foundation, exploring:

  • Personalized Probiotic Therapies: Tailoring probiotic formulations to individual microbiome profiles for personalized health benefits.
  • Multi-Strain Encapsulation: Developing encapsulation techniques for multiple probiotic strains to create synergistic effects and enhance gut health.

🎓Publication 

Food waste leachate valorization for sustainable biomass production from Arthrospira maxima

Microencapsulation and controlled release of Bacillus clausii through a novel non-digestible carbohydrate formulation as revolutionizing probiotic delivery

    • Authors :Ramirez-Olea, H., Herrera-Cruz, S., Chavez-Santoscoy, R.A.
    • Journal   :Heliyon
    • Year       : 2024

Microencapsulation and controlled release of Bacillus clausii through a novel non-digestible carbohydrate formulation as revolutionizing probiotic delivery

  • Authors  :Ramirez-Olea, H., Herrera-Cruz, S., Chavez-Santoscoy, R.A.
  • Journal    :Heliyon
  • Year         :  2024

Synthesis and evaluation of Maillard conjugates for encapsulation and controlled delivery of quercetin under simulated gastrointestinal tract conditions

 

Essential-Oils-Loaded Biopolymeric Nanoparticles as Strategies for Microbial and Biofilm Control: A Current Status

Prof Dr. ASHOK KUMAR SHAKYA |Drug Discovery and Development| Best Researcher Award-1226

Prof Dr. ASHOK KUMAR SHAKYA ,Drug Discovery and Development ,Best Researcher Award

Prof Dr. ASHOK KUMAR SHAKYA, at AL-AHLIYYA AMMAN UNIVERSITY ,Jordan

 Profile

Google scholar

    

🎓Early Academic Pursuits

Prof. Dr. Ashok K. Shakya’s academic journey began at Dr. Harisingh Gour University, Sagar (A Central University), India. He earned his Bachelor of Science in 1986, followed by a Master of Pharm. Science in 1988. His academic excellence continued as he pursued a Ph.D. in Pharmaceutical Sciences, which he completed in 1992. His doctoral research focused on the “Synthesis and Pharmacological Evaluation of Some 1:3:4 Thiadiazole Derivatives,” where he synthesized various thiadiazole derivatives and evaluated their pharmacological activities, including CNS depressant, anti-inflammatory, hypotensive, and diuretic effects.

Professional Endeavors

Dr. Shakya’s professional career spans over three decades, marked by significant contributions to pharmaceutical education and research. He began his teaching career as an Assistant Professor at Dr. Harisingh Gour University in 1988. He later held positions at Integral University, Lucknow, India, where he served as the Head of the Faculty of Pharmacy and contributed to establishing Master’s and Ph.D. programs.

In 1995, Dr. Shakya joined Ranbaxy Research Laboratories as a Manager in the Division of Clinical Pharmacology, Pharmacokinetics & Drug Metabolism. Here, he developed and validated various analytical methods for new and existing drug molecules, playing a crucial role in clinical studies (PK/BE/BA).

Since 2008, Dr. Shakya has been associated with Al-Ahliyya Amman University, Jordan. He served as an Assistant Professor, Associate Professor, and currently as a Professor in the Faculty of Pharmacy. He has been instrumental in teaching, research, and curriculum development. His administrative roles include Vice Dean of University Scientific Research and Assistant Dean of PDRC, where he established state-of-the-art research facilities and promoted research collaborations.

Contributions and Research Focus

Dr. Shakya’s research expertise encompasses Medicinal Chemistry, Pharmaceutical Analysis, Phytopharmaceuticals, Formulation Development, and Peptide Synthesis. He has developed several analytical and bioanalytical techniques for new chemical entities (NCE), investigational new drugs (IND), and abbreviated new drug applications (ANDA). His contributions include establishing GLP-compliant animal houses and staying abreast of current trends in cGMP, cGCP, and Good Laboratory Practices.

Dr. Shakya has filed two patents on anticancer and antitubercular agents. His skills extend to various analytical techniques, including LCMSMS, GC-MSMS, UPLC, and molecular modeling. He has also synthesized peptides and peptidomimetics, contributing to the field of drug design and discovery.

Accolades and Recognition

Dr. Shakya’s work has been recognized at numerous international conferences. He has presented his research at prestigious events such as the Eurasia Pharmacy Conference in Turkey, the International Conference on New Trends in Chemometrics and Applications in Turkey, and the Propolis-Human and Bee Health Conference in Bulgaria. His keynote address at the Best Med Grape conference in Beirut, Lebanon, highlights his standing in the scientific community.

Impact and Influence

As an educator and mentor, Dr. Shakya has guided over 70 master’s students, enhancing their research skills and helping them achieve their academic goals. His influence extends beyond teaching, as he has been involved in grant proposal writing, technical report authoring, and the procurement of sophisticated scientific equipment.

Dr. Shakya’s administrative roles have significantly impacted the research environment at Al-Ahliyya Amman University. He has promoted a culture of continuous quality management, encouraging faculty to publish in high-impact journals and facilitating research collaborations. His efforts have contributed to the university’s improved QS ranking and scientific reputation.

Legacy and Future Contributions

Dr. Shakya’s legacy lies in his unwavering commitment to advancing pharmaceutical sciences. His work in developing new analytical methods, synthesizing bioactive compounds, and mentoring future scientists has left an indelible mark on the field. As he continues his academic and research endeavors, Dr. Shakya remains dedicated to pushing the boundaries of pharmaceutical research and education.

🎓Publication 

Antioxidant activity of some common plants

  • Authors   :Nooman A Khalaf, Ashok K Shakya, A. Al-Othman, Zaha El-Agbar
  • Journal    :Turk J. Biol.
  • Year         : 2008

Orotransmucosal drug delivery systems: a review

    • Authors :NV Satheesh Madhav, Ashok K Shakya, Pragati Shakya, Kuldeep Singh
    • Journal   :Journal of controlled release
    • Year       : 2009

Palatal mucosa as a route for systemic drug delivery: A review

  • Authors  :Pragati Shakya, NV Satheesh Madhav, Ashok K Shakya, Kuldeep Singh
  • Journal    :Journal of controlled release
  • Year         :  2011

Fatty acids analysis, antioxidant and biological activity of fixed oil of Annona muricata L. seeds

  • Authors  :Z. Elagbar, R.R. Naik, Ashok K. Shakya, Sanaa K. Bardaweel
  • Journal   :Journal of Chemistry
  • Year        :   2016

 

Estimation of gallic acid, rutin and quercetin in Terminalia chebula by HPTLC

  • Authors  :Ashok Kumar, K Lakshman, KN Jayaveera, S Mani Tripathi, KV Satish
  • Journal   : Jordan J Pharm Sci
  • Year        :   2010